Dual bronchodilator therapy in COPD ‘may raise heart risk’
Prescribers need to bear this in mind considering the extra benefit is only modest,, researchers say
People with COPD who use two forms of long-acting bronchodilator concomitantly have more than a 50% higher risk of acute coronary syndrome than those who use a long-acting muscarinic antagonist (LAMA) alone, a study suggests.
“This is important because coronary events are responsible for more deaths than respiratory failure in patients with COPD,” the authors say.
